Mounjaro (tirzepatide) is a weekly injection for weight management that works differently from earlier GLP-1 medications. While semaglutide (Wegovy, Ozempic) targets a single hormone receptor, tirzepatide targets two - GLP-1 and GIP - giving it a dual mechanism of action. In Singapore, it is available as a prescription medication and has become an increasingly discussed option for medically supervised weight management.
GLP-1 (glucagon-like peptide-1) is a gut hormone that signals fullness to the brain, slows gastric emptying, and helps regulate blood sugar. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that also plays a role in fat metabolism and appetite regulation. Tirzepatide activates both receptors simultaneously, which researchers believe contributes to a stronger effect on appetite and weight than GLP-1 agonism alone.
Patients looking for detailed clinical information on Mounjaro as it is offered in Singapore can visit https://weightlossclinic.sg/mounjaro-tirzepatide-singapore/. One clinic providing this treatment is Edwin Lim Clinic at 304 Orchard Rd, #05-51A Lucky Plaza, Singapore 238863 (tel: 9637 2218).
Mounjaro’s weight loss evidence comes primarily from the SURMOUNT clinical trial programme. SURMOUNT-1, which enrolled adults with obesity and without type 2 diabetes, showed mean weight reductions of 20.9% at the 10mg dose and 22.5% at the 15mg dose at 72 weeks. These figures were notably higher than those seen in semaglutide trials, though direct head-to-head comparisons between the two drugs are limited in the published evidence.
SURMOUNT-2 studied the drug in adults with type 2 diabetes and obesity, showing clinically meaningful weight loss alongside improved glycaemic control. The dual mechanism is considered particularly relevant for patients whose weight management challenges intersect with metabolic conditions.
Like other GLP-1-based medications, Mounjaro uses a gradual dose escalation approach to reduce gastrointestinal side effects:
Not all patients reach or need the maximum dose. The appropriate maintenance dose is determined by the treating doctor based on the patient’s response and tolerance.
Mounjaro is given as a subcutaneous injection into the abdomen, thigh, or upper arm, once per week. Patients are shown how to self-administer the injection during their clinical appointment. Injection sites should be rotated to avoid repeated injection into the same area.
As with other prescription weight loss medications, Mounjaro is prescribed based on individual assessment. Generally, it is considered for adults with a BMI of 30 or above, or a BMI of 27 or above with a weight-related condition such as type 2 diabetes, hypertension, or dyslipidaemia. A doctor must assess suitability before prescribing.
Mounjaro may be of particular interest for patients with both weight management goals and metabolic concerns such as pre-diabetes or type 2 diabetes, given its dual mechanism and the evidence from both SURMOUNT-1 and SURMOUNT-2.
The most frequently reported side effects of tirzepatide are gastrointestinal in nature - nausea, vomiting, diarrhoea, constipation, and abdominal discomfort. These tend to occur most during the dose escalation phase and often reduce as the body adjusts to the medication. The gradual titration schedule is specifically designed to minimise these effects.
Mounjaro requires a doctor’s prescription and cannot be purchased legally through non-clinical channels. The prescribing process involves an initial consultation, a clinical assessment, and - if appropriate - a prescription with a structured treatment and monitoring plan.